Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105537 | 0.94 | PPARG (0.64) | PPARGTP53MDM2SCN9APTGER1 | |
| SCHEMBL5106602 | 0.90 | PPARG (0.61) | PPARGTP53MDM2MEN1KMT2A | |
| SCHEMBL5119469 | 0.90 | PPARG (0.68) | PPARGTP53MDM2SCN9A | |
| SCHEMBL5108822 | 0.89 | PPARG (0.81) | PPARGPTGER1 | |
| SCHEMBL5119547 | 0.89 | PPARG (0.81) | PPARGTP53MDM2MEN1PKM | |
| SCHEMBL5121992 | 0.88 | PPARG (0.55) | PPARGTP53MDM2 | |
| SCHEMBL5114403 | 0.87 | PPARG (0.58) | PPARGTP53MDM2 | |
| SCHEMBL5109320 | 0.86 | PPARG (0.81) | PPARGPTGER1 | |
| SCHEMBL5113215 | 0.83 | PPARG (0.83) | PPARGPTGER1 | |
| SCHEMBL5112360 | 0.83 | PPARG (0.77) | PPARGTP53MDM2SCN9APTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885TP53 4637/4885MDM2 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.